Introduction
The menopause is the transition from the reproductive to the non-reproductive stage of life in women and is characterized clinically by permanent cessation of menstruation and biologically by loss of ovarian function. The menopause occurs around a mean age of 50 years; virtually all women by the age of 55 years or so will have experienced the menopause. The changes in birth and mortality rates over the last century and, in particular, the profound decline in maternal mortality in developed countries have resulted in an average life expectancy of women of about 75 years; thus, most women will be postmenopausal for one third of their lifetime. Such women (9 million in England and Wales) now comprise about 18% of the total population. The aim of this review is to highlight current issues concerning the menopause and hormone replacement therapy, hence literature cited is not intended to be comprehensive but indicative. This article will briefly describe the epidemiology of the menopause, summarize the epidemiological data concerning hormone replacement therapy, the questions these raise and the implications these have concerning health in postmenopausal women.
Definitions ofthe menopause
A World Health Organization report on the menopause' suggested the following definitions.
1. The menopause should be defined as the permanent cessation of menstruation resulting from loss of ovarian follicular activity. 2. The perimenopause (or climacteric) should be used to include the period immediately prior to the menopause with endocrinological, biological and clinical features of approaching menopause, and at least the first year after the menopause.
3. The postmenopause should be defined as dating from the menopause, although it cannot be determined until after a period of 12 months of spontaneous amenorrhea has been observed. Though the diagnosis of menopause is based on clinical signs and symptoms, primarily amenorrhoea, and confirmed when necessary with assays for steroid hormones or gonadotrophins, the loss of ovarian function is the essential characteristic of menopause. Thus, a surgical menopause occurs after bilateral oophorectomy with or without hysterectomy, but would not include cessation of menstruation following a simple hysterectomy.
Age at menopause
The median age at menopause in most Western industrialized societies has been shown to be remarkably constant, around 50 If it is the case that risk of breast cancer associated with hormone replacement therapy is related to duration of use and/or is increased with oestradiol compounds or the addition of progestogens, this raises issues of concern about optimal formulations or duration of therapy. The current trend is towards increasing duration of hormone replacement therapy since the benefits in terms of fracture prevention would seem to require long term (at least 6-10 years' use), and there has been a proliferation of different hormonal formulations. Even a small increase in risk is possibly of greater concern since breast cancer is substantially commoner than endometrial cancer and generally perceived as a worse disease to suffer. 54 It is not clear how much the observed reduced risk in these studies is due to the selection bias of healthier women being more likely to be users of hormone replacement therapy, but the general consensus from the available evidence is that the cardioprotective effect ofoestrogens is real.
The most plausible biological mechanism for the apparent protective effect of oestrogens on coronary heart disease risk is via lipid levels. Both observational and trial data have shown that oestrogens increase high density lipoprotein (HDL) cholesterol levels, which are beneficial for coronary heart disease;23'6'-63 indeed, it has been suggested that oestrogen therapy might be first line treatment for hypercholesterolaemia. Little is known about the long-term effect of combined (oestrogen plus progestogen) therapy on coronary heart disease risk. Of concern, however, are observations that the addition ofprogestogens, in particular the more androgenic formulations such as norethisterone, reduces the HDL-cholesterol raising effect of oestrogens.63 How much the suggested protective effect of oestrogen may be mediated through the effect on lipids and how much through other mechanisms, such as clotting factors,5164 or vascular reactivity65 is undetermined. The major uncertainty concerning the impact of hormone replacement therapy on coronary heart disease is what effect adding progestogen has.
The evidence for stroke is more equivocal;66-70 this might be related to the fact that raised blood pressure rather than lipid profile is the main risk factor for stroke. This implies understanding not just the qualitative relationship between the intervention and various outcomes but also a quantitative assessment. This can be illustrated by an example using data on British women to estimate the effect of hormone replacement therapy and based on the simplest assumptions. For this analysis, annual disease rates by 10 year age groups for women, were obtained from the Office of Population Censuses and Surveys statistics for England and Wales. Breast, endometrial, coronary heart disease and stroke mortality rates were obtained from mortality statistics;" since hip fracture mortality figures are unreliable, incidence rates were estimated using the Hospital Inpatient Enquiry;72 these hip fracture incidence rates are of the same order as those estimated by Boyce and Vessey." Assuming that all women had been using hormone replacement therapy for 10 years, relative risks for each disease associated with hormone replacement therapy, either unopposed oestrogen or oestrogen plus progestogen were derived from data reviewed earlier. Table I shows the estimated changes in annual rates by 10 year age category for various disease endpoints associated with hormone replacement therapy, either unopposed oestrogen or oestrogen with progestogen. This demonstrates how the overall impact of an intervention on any disease depends not just on the relative risk, but on the absolute rates of that disease; thus, a small percentage reduction in a common condition such as cardiovascular disease has a much greater numerical impact in the population than a large percentage change in risk for a rare condition such as endometrial cancer. In this model, we assume that adding progestogen to oestrogen abolishes the excess risk from endometrial cancer completely, group.bmj.com on June 20, 2017 -Published by http://pmj.bmj.com/ Downloaded from but reduces the cardiovascular benefit. Because cardiovascular disease contributes a much greater number of events compared to endometrial cancer, the effect of adding progestogen to oestrogen is to reduce the overall net benefit, since abolishing the excess risk from endometrial cancer is more than counterbalanced by the reduction of the benefit for cardiovascular disease which is small in relative, but large in absolute terms. The age categories illustrate how, even with fixed relative risk, the overall risk-benefit balance changes depending on the absolute rates of the various conditions. At younger ages, where rates ofcardiovascular disease and fracture are low, overall the risk-benefit ratio is neutral; cardiovascular disease and fracture rates but not cancer rates rise exponentially with age such that at older ages, the risk-benefit ratio overwhelmingly favours hormone replacement therapy.
The estimates shown are compatible with observations from several epidemiological studies indicating lower all cause mortality in hormone replacement therapy users compared to nonusers.56 '60 However, this simple model is meant only to be illustrative, not definitive. Detailed costbenefit analyses have been conducted elsewhere. [74] [75] [76] This model is intended only to show how overall risk-benefit ratios depend on the absolute rates of the disease and are sensitive to small changes and hence cannot be universally applied: for example, in populations where absolute rates of cardiovascular disease and hip fracture may be low or reproductive cancer high, such as in certain age or ethnic groups, the balance ofrisk, and also the cost, to benefit will change substantially.
Hormone replacement therapy. current issues
The clinical use of hormone replacement therapy for specific relief of menopausal symptoms such as vaginitis or hot flushes is well accepted. The major debate concerning hormone replacement therapy is whether widespread general use should be encouraged as a policy in asymptomatic healthy postmenopausal women for prevention of osteoporosis and cardiovascular disease. While short-term trials indicate beneficial effects of oestrogens on intermediate variables such as bone mineral density and on lipid profiles, the assumption of longer term benefits for clinical endpoints such as fractures, heart attacks or strokes rest upon observational studies which may suffer from selection bias for healthy users. There are some anxieties about increased risk of reproductive cancers which may not entirely be resolved by the addition of progestogens. The major uncertainties are in the quantification of the overall long-term benefits and risks associated with prolonged use.
Questions concerning these uncertainties include the following:
1. The type ofhormone There are now dozens of different preparations available but it is notable that the bulk of the epidemiological data indicating benefits and risks of oestrogens was based on preparations using conjugated equine oestrogens. Different oestrogen and progestogen formulations do not necessarily have identical actions, and it is not known how far these effects can be generalized to other oestrogens now being marketed. In at least one study, oestradiol compounds appeared to be more strongly associated with breast cancer risk. The major question concerns the addition of progestogens. The benefit of progestogens is to reduce the endometrial cancer risk. Progestogens do not appear to affect the benefits of oestrogens for osteoporosis. However, there is some evidence that some progestogens, particularly the androgenic formulations currently most commonly used, may negate the high density lipoprotein-cholesterol raising effect, and hence, cardiovascular protective effect of oestrogen therapy. There is also some concern that the addition of progestogens may potentiate breast cancer risk. 2. Method ofapplication Different modes of hormonal application such as transdermal or depot preparations are now available. The resultant blood levels, as well as metabolic consequences of these may be quite different from the oral preparations on which the epidemiological data were based. While such preparations may be more effective for symptomatic treatment, there are only limited clinical studies with respect to the long-term effects, beneficial and otherwise, of these on osteoporosis, cardiovascular disease, and cancer. 3. Duration of use If the main aim is relief of perimenopausal syptoms, women are likely to continue for the length of time that provides such relief. However, if the main indication is to prevent osteoporosis, therapy may need to be continued for longer periods, possibly 6 years or substantially more to prevent fractures. The dilemma is that such long-term use may be associated with increasing risk of breast cancer.
Several prospective population studies, mostly in the United States, are continuing surveillance of women on postmenopausal hormone replacement therapy. A multicentre trial to compare the effects of different hormone formulations including unopposed oestrogens versus combined oestrogen and progestogen preparation on lipid profiles (PEPI) is currently under way in the United States.
However, it is argued that long-term randomized controlled trials of hormone replacement therapy which have the capacity to examine the effects on clinical endpoints including mortality are required before we can feel entirely comfortable about recommending its use as a universal prophylactic therapy in asymptomatic women.
Currently, the bulk of the evidence indicates hormone replacement therapy appears to have considerable general benefits and few would argue that every postmenopausal woman should have the opportunity at least to consider hormone replacement therapy. However, individual women and their medical practitioners need to be clear about their main reasons for the use of hormone replacement therapy: whether for short term relief of symptoms or for longer term prophylaxis since the optimal formulations, mode of administration and duration of use may differ according to the main indication for therapy; as Barrett-Connor33 suggests, ... 'choices must consider more than the possible prevention of one specific disease, but also issues of the individual woman's risk pattern, fears and quality of life.'
The menopause: epidemiological aspects Despite abundant research on hormone replacement therapy, current knowledge about many questions concerning the menopause is still sparse. These questions include the incidence and frequency ofmenopause-related conditions in different populations, the role of endogenous sex hormones in the aetiology of symptoms and chronic diseases associated with the menopause and the role of exogenous factors which might influence either hormonal levels or the incidence of such menopause-related conditions. Hormone replacement therapy is only one dimension in a large range of factors which are only just beginning to be explored.
Epidemiological data suggest that the incidence ofmany ofthe conditions that we associate with the menopause, including both symptomatology and chronic diseases such as osteoporosis, vary widely between different populations and hence are not necessarily inevitable consequences of the menopause. While comparisons of the frequency of vasomotor, psychological and gynaecological symptoms in different studies are difficult, due to different definitions and study methods, some researchers have attempted to use standardized ascertainment and criteria enabling cross-cultural comparisons. Night sweats, hot flushes and palpitations have been attributed to vasomotor instability, and are reported to affect approximately 75% ofmenopausal women.7-79 A Canadian study indicated a frequency of 65% of perimenopausal women reporting hot flushes at some time in the past.22 However, using identical methodology to the Canadian study, only 20% of the women in a Japanese survey reported hot flushes.80 Psychological symptoms such as depression and tiredness reported affect 25% of perimenopausal women in the Netherlands8' but were documented only by 5-10% of Japanese women. 80 We do not know why such wide variation in symptoms occur, nor do we understand the specific mechanisms; in particular, the role of oestrogen deficiency is still debated. 82 Similarly, the importance of endogenous oestrogen levels in the aetiology of chronic disease is also unclear. Within populations, changing from pre-to postmenopausal status is associated with increased cardiovascular risk, independent of age.83 '84 This suggests that low levels ofoestrogens are associated with increased cardiovascular disease risk. However, data from the World Health Organisation85 in Table II , which shows age-specific death rates for women by age group by selected causes of death in England and Wales, and Japan, also indicate that considerable variation exists in chronic diseases thought to be oestrogen related such as breast cancer and cardiovascular disease. Since Japanese women have generally lower oestrogen levels than Caucasian women,86 the considerably lower cardio- Numerous exogenous factors such as diet, cigarette smoking habit and physical activity, which affect risk of chronic disease also influence endogenous sex hormone levels, but little is understood about the possible mechanisms. For example, high fat intakes have been associated with higher endogenous androgens or oestrogen levels, while a diet high in plant foods or increased physical activity is associated with lower oestrogen and increased sex hormone-binding globulin levels.86"88-Cigarette smoking habit has been shown to reduce oestrogen and increase androgen levels in postmenopausal women.9' 93 Oestrogen therapy not only, as expected, increases levels of circulating oestrogens but also has effects on other hormones including a decrease in endogenous androgens and increase in sex hormone-binding globulin and cortisol levels. 94 The work on tamoxifen provides an illustration of potential new areas for exploration. Tamoxifen is a competitive oestrogen inhibitor, initially used in therapy of established breast cancer; trials of tamoxifen therapy for primary prevention ofbreast cancer in high-risk women are underway or being planned.95 However, tamoxifen has also been documented to have some oestrogen-like agonistic activity, and is associated both with increasing high-density lipoprotein levels as well as increasing bone density.
While issues such as the long-term effects of tamoxifen are still debated, this has raised the possibility of other partial oestrogen agonists, which may have advantages without the disadvantages ofoestrogen therapy. For example, phytooestrogens, found in plant foods, appear to have weak oestrogenic agonist as well as antagonist effects,' which may explain the observation that high soya bean intake is not only protective for breast cancer,97 possibly through an anti-oestrogenic effect at the breast site, but also appears beneficial for cardiovascular risk through influencing lipids.
Optimum management of the menopause and the postmenopausal years will depend on identifying factors which influence the incidence of conditions associated with the menopause and their possible mechanisms. It is still not clear how far these conditions are due to oestrogen deficiency and can be remedied by hormone replacement therapy. However, the variations in postmenopausal health between different populations and profound changes over time indicate the potential for improvement, as well as several promising directions for research.
